Ligand's $460 Million Of 2030 Convertible Notes Are Now Current Debt Holders Can Convert
Ligand must settle principal in cash if holders convert, and cash and investments fell to $447.4 million after the XOMA purchase.
Ligand Pharmaceuticals, a royalty company that buys and structures royalty interests in drugs developed by other companies, now carries its $460.0 million in 2030 convertible notes as a current liability, its 10-Q filed Friday shows. The conversion conditions were met as of September 30, so holders can convert through December 31, 2026.
Cash must cover the principal
Upon conversion, Ligand must pay the principal in cash and may pay any excess value in cash, shares or both. The notes sit on the balance sheet as a current liability of $448.3 million, net of unamortized discount and issuance costs. The prior quarter's 10-Q carried them as noncurrent.
No holder had submitted notes for conversion as of September 30. The notes' current status will be retested at every quarter-end against the conversion condition.
Management says cash, short-term investments and the revolving credit facility are enough to settle the principal in cash if every holder converts. Ligand also expects those same resources to cover operations, debt service and acquisitions over at least the next twelve months. The prior quarter's wording had tied funding to the next twelve months "and into 2027."
Cash down to $447.4 million
Cash, cash equivalents and short-term investments stood at $447.4 million on September 30, compared with $733.5 million at December 31, 2025. Ligand attributes the drop mainly to the XOMA Royalty acquisition and other deals, partly offset by proceeds from the $700.0 million of 2031 notes it sold in June. Net proceeds were about $679.0 million.
The amended revolver, with $125.0 million in commitments, had no borrowings and $124.4 million available. XOMA's preliminary purchase price was $887.0 million, including $691.7 million paid at $39.00 per share. Ligand got control on July 14.
The quarter showed a net loss of $28.5 million, or $1.43 per share, as general and administrative costs rose to $72.6 million from $28.4 million. Of that, $14.2 million was XOMA transaction costs. Royalties rose 51% to $70.3 million, helped by the XOMA assets, Filspari and Ohtuvayre.
A bigger royalty book
XOMA adds seven commercial products, 14 late-stage programs and more than 100 other assets, taking Ligand's portfolio to over 200 royalty assets. Ligand also bought a royalty interest in Santen's Ryjunea for $23 million and committed up to $41 million to AvenCell for a royalty on its pipeline.
In its earnings release, Ligand raised its 2026 adjusted earnings guidance to $9.50 to $9.75 per diluted share, from $9.00 to $9.50, and kept its revenue guidance.
Holders can convert through December 31, 2026, and the next quarter-end test decides whether the notes remain current.
Sources
- 10-Q Filing — Ligand Pharmaceuticals (LGND) — SEC EDGAR
- 10-Q Filing — Ligand Pharmaceuticals (LGND), Q2 FY2026 filed 2026-08-07 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, q32026earningsrelease_ex991.htm) — Ligand Pharmaceuticals, filed 2026-10-29 — SEC EDGAR
- Ligand Pharmaceuticals Inc (LGND) (Q3 2026) Earnings Call Highlights: Royalty Revenue Surges ... — Yahoo Finance
- Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty Strength — Yahoo Finance
- Ligand: Q3 Earnings Snapshot – WTOP News — wtop.com
- Ligand Pharmaceuticals Non-GAAP EPS of $2.67 beats by $0.34, revenue of $78.75M beats by $1.52M (NASDAQ:LGND) | Seeking Alpha — seekingalpha.com
- Ligand: Q3 Earnings Snapshot | khou.com — Associated Press